IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
iBio, Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 28, 2026
$0.76−0.01 (-0.81%)
Close on Oct 19, 2026
- Market cap
- $110.48M
- P/E (TTM)
- –
- Dividend yield
- –
iBio, Inc. revenue by segment
By business segment
| Revenue | TTM Q4 26 | TTM Q4 25 | TTM Q4 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceuticals (iBio, Inc.) [Member] | – | – | $1.88M | $1.10M | $2.22M | $1.59M | $1.65M | $1.55M | $1.22M | $1.67M | $2.08M | $2.02M | – | – |
| Bioprocessing (iBio CDMO) [Member] | – | – | $499.00K | $1.27M | – | – | – | – | $93.00K | $72.00K | $0 | $0 | – | – |
| Operating income | TTM Q4 26 | TTM Q4 25 | TTM Q4 22 | TTM Q4 21 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biopharmaceuticals (iBio, Inc.) [Member] | – | – | -$29.19M | -$14.70M | -$10.64M | -$7.74M | -$5.58M | -$4.15M | -$4.78M | -$4.41M | -$5.13M | -$5.16M | – |
| Bioprocessing (iBio CDMO) [Member] | – | – | -$20.50M | -$16.41M | -$13.97M | -$13.73M | -$11.49M | -$9.86M | -$10.34M | -$10.41M | -$10.55M | -$10.63M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of iBio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.